Does fluvastatin reduce cardiac mortality in patients with coronary heart disease?
This meta-analysis demonstrates clear beneficial effects of fluvastatin on cardiac and all-cause mortality in CHD patients, and supports the use of fluvastatin to reduce the incidence of MACE in a wide range of at-risk patients.
We demonstrated evidence of a correlation between low femoral BMD levels and risk of vertebral fractures in patients with AS, especially at the intertrochanteric area. Longitudinal studies in a large population are required to determine the diagnostic implications of femur BMD for increased risk of vertebral fractures in AS.